{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:15:45Z","timestamp":1790914545209,"version":"4.1.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T00:00:00Z","timestamp":1621555200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T00:00:00Z","timestamp":1621555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["Forschungsfoerderung 2016"],"award-info":[{"award-number":["Forschungsfoerderung 2016"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["Forschungsfoerderung 2016"],"award-info":[{"award-number":["Forschungsfoerderung 2016"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Universit\u00e4tsklinikum D\u00fcsseldorf. Anstalt \u00f6ffentlichen Rechts"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Tofacitinib is a novel Janus kinase (JAK) inhibitor approved for the treatment of rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. In clinical trials, the most common adverse events observed were nasopharyngitis, upper respiratory tract infections, and zoster. JAKs are found downstream of the type II cytokine receptor family used by a number of T<jats:sub>H<\/jats:sub>17 cell-associated cytokines for signal transduction. These cytokines lead to the secretion of antiviral and antimicrobial peptides (AMPs) by keratinocytes or synoviocytes. Blocking the JAK pathway might result in a diminished secretion of antimicrobial and antiviral peptides causing higher susceptibility to infections in patients treated with JAK inhibitors.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We treated primary human keratinocytes and synoviocytes with tofacitinib and subsequently added various cytokines and bacterial surface proteins before evaluation of the response via RT-qPCR. CD69 expression on tofacitinib-treated PBMCs was investigated via flow cytometry.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We found a markedly reduced gene expression of all tested antiviral peptides such as MX1 or ISG15 in keratinocytes and synoviocytes in the presence of tofacitinib in vitro. Additionally, we found that JAK inhibition reduced activation of T cells after stimulation with bacterial LPS or viral VZV gE.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The antiviral immunity is strongly inhibited in the presence of tofacitinib in vitro, while the antimicrobial immunity does not seem to be affected. In T cells, the overall activation process seems to be influenced by tofacitinib. These findings suggest that tofacitinib has an impact on antiviral immunity such as patients treated with tofacitinib often show adverse events like herpes zoster.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphical abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1186\/s13075-021-02509-8","type":"journal-article","created":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T07:02:55Z","timestamp":1621580575000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Tofacitinib downregulates antiviral immune defence in keratinocytes and reduces T cell activation"],"prefix":"10.1186","volume":"23","author":[{"given":"Heike C.","family":"Hawerkamp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Domdey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Radau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Sewerin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e9ter","family":"Ol\u00e1h","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Homey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Meller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,21]]},"reference":[{"issue":"16","key":"2509_CR1","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","volume":"377","author":"P Mease","year":"2017","unstructured":"Mease P, Hall S, FitzGerald O, van der Heijde D, Merola JF, Avila-Zapata F, Cie\u015blak D, Graham D, Wang C, Menon S, Hendrikx T, Kanik KS. Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N Engl J Med. 2017;377(16):1537\u201350. https:\/\/doi.org\/10.1056\/NEJMoa1615975.","journal-title":"N Engl J Med"},{"issue":"2","key":"2509_CR2","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s40744-018-0113-7","volume":"5","author":"V Strand","year":"2018","unstructured":"Strand V, Kavanaugh A, Kivitz AJ, van der Heijde D, Kwok K, Akylbekova E, Soonasra A, Snyder M, Connell C, Bananis E, Smolen JS. Long-term radiographic and patient-reported outcomes in patients with rheumatoid arthritis treated with tofacitinib: ORAL start and ORAL scan post-hoc analyses. Rheumatol Ther. 2018;5(2):341\u201353. https:\/\/doi.org\/10.1007\/s40744-018-0113-7.","journal-title":"Rheumatol Ther"},{"issue":"18","key":"2509_CR3","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","volume":"376","author":"WJ Sandborn","year":"2017","unstructured":"Sandborn WJ, Su C, Sands BE, D'Haens GR, Vermeire S, Schreiber S, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376(18):1723\u201336. https:\/\/doi.org\/10.1056\/NEJMoa1606910.","journal-title":"N Engl J Med"},{"issue":"11","key":"2509_CR4","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1002\/jcph.734","volume":"56","author":"M Lamba","year":"2016","unstructured":"Lamba M, Wang R, Fletcher T, Alvey C, Kushner J, Stock TC. Extended-release once-daily formulation of tofacitinib: evaluation of pharmacokinetics compared with immediate-release tofacitinib and impact of food. J Clin Pharmacol. 2016;56(11):1362\u201371. https:\/\/doi.org\/10.1002\/jcph.734.","journal-title":"J Clin Pharmacol"},{"key":"2509_CR5","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/1476-9255-7-41","volume":"7","author":"DM Meyer","year":"2010","unstructured":"Meyer DM, Jesson MI, Li X, Elrick MM, Funckes-Shippy CL, Warner JD, et al. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1\/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. J Inflamm (London). 2010;7:41.","journal-title":"J Inflamm (London)"},{"issue":"1","key":"2509_CR6","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/nrrheum.2012.190","volume":"9","author":"N Bottini","year":"2013","unstructured":"Bottini N, Firestein GS. Duality of fibroblast-like synoviocytes in RA: passive responders and imprinted aggressors. Nat Rev Rheumatol. 2013;9(1):24\u201333. https:\/\/doi.org\/10.1038\/nrrheum.2012.190.","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"2509_CR7","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/j.0105-2896.2009.00859.x","volume":"233","author":"B Bartok","year":"2010","unstructured":"Bartok B, Firestein GS. Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunol Rev. 2010;233(1):233\u201355. https:\/\/doi.org\/10.1111\/j.0105-2896.2009.00859.x.","journal-title":"Immunol Rev"},{"issue":"2","key":"2509_CR8","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1136\/ard.41.2.177","volume":"41","author":"JC Edwards","year":"1982","unstructured":"Edwards JC, Willoughby DA. Demonstration of bone marrow derived cells in synovial lining by means of giant intracellular granules as genetic markers. Ann Rheum Dis. 1982;41(2):177\u201382. https:\/\/doi.org\/10.1136\/ard.41.2.177.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"2509_CR9","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1136\/ard.2005.050385","volume":"65","author":"JG Walker","year":"2006","unstructured":"Walker JG, Ahern MJ, Coleman M, Weedon H, Papangelis V, Beroukas D, Roberts-Thomson PJ, Smith MD. Changes in synovial tissue Jak-STAT expression in rheumatoid arthritis in response to successful DMARD treatment. Ann Rheum Dis. 2006;65(12):1558\u201364. https:\/\/doi.org\/10.1136\/ard.2005.050385.","journal-title":"Ann Rheum Dis"},{"key":"2509_CR10","unstructured":"Veale DJ, Fitzgerald O. Psoriatic arthritis - pathogenesis and epidemiology. Clin Exp Rheumatol. Nov-Dec 2002;20(6 Suppl 28):S27\u201333."},{"issue":"2","key":"2509_CR11","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1136\/annrheumdis-2018-214065","volume":"78","author":"P Sewerin","year":"2019","unstructured":"Sewerin P, Brinks R, Schneider M, Haase I, Vordenb\u00e4umen S. Prevalence and incidence of psoriasis and psoriatic arthritis. Ann Rheum Dis. 2019;78(2):286\u20137. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214065.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"2509_CR12","doi-asserted-by":"publisher","first-page":"441","DOI":"10.2165\/00128071-200304070-00001","volume":"4","author":"H Zachariae","year":"2003","unstructured":"Zachariae H. Prevalence of joint disease in patients with psoriasis: implications for therapy. Am J Clin Dermatol. 2003;4(7):441\u20137. https:\/\/doi.org\/10.2165\/00128071-200304070-00001.","journal-title":"Am J Clin Dermatol"},{"issue":"10","key":"2509_CR13","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/nri2622","volume":"9","author":"FO Nestle","year":"2009","unstructured":"Nestle FO, Di Meglio P, Qin J-Z, Nickoloff BJ. Skin immune sentinels in health and disease. Nat Rev Immunol. 2009;9(10):679\u201391. https:\/\/doi.org\/10.1038\/nri2622.","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"2509_CR14","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1038\/jid.2013.500","volume":"134","author":"K Taniguchi","year":"2014","unstructured":"Taniguchi K, Arima K, Masuoka M, Ohta S, Shiraishi H, Ontsuka K, Suzuki S, Inamitsu M, Yamamoto KI, Simmons O, Toda S, Conway SJ, Hamasaki Y, Izuhara K. Periostin controls keratinocyte proliferation and differentiation by interacting with the paracrine IL-1alpha\/IL-6 loop. J Invest Dermatol. 2014;134(5):1295\u2013304. https:\/\/doi.org\/10.1038\/jid.2013.500.","journal-title":"J Invest Dermatol"},{"issue":"1","key":"2509_CR15","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.jdermsci.2012.10.004","volume":"69","author":"JH Peters","year":"2013","unstructured":"Peters JH, Tjabringa GS, Fasse E, de Oliveira VL, Schalkwijk J, Koenen HJ, et al. Co-culture of healthy human keratinocytes and T-cells promotes keratinocyte chemokine production and RORgammat-positive IL-17 producing T-cell populations. J Dermatol Sci. 2013;69(1):44\u201353. https:\/\/doi.org\/10.1016\/j.jdermsci.2012.10.004.","journal-title":"J Dermatol Sci"},{"issue":"24","key":"2509_CR16","doi-asserted-by":"publisher","first-page":"11960","DOI":"10.1128\/JVI.01678-06","volume":"80","author":"JC Jones","year":"2006","unstructured":"Jones JC, Turpin EA, Bultmann H, Brandt CR, Schultz-Cherry S. Inhibition of influenza virus infection by a novel antiviral peptide that targets viral attachment to cells. J Virol. 2006;80(24):11960\u20137. https:\/\/doi.org\/10.1128\/JVI.01678-06.","journal-title":"J Virol"},{"issue":"204","key":"2509_CR17","doi-asserted-by":"publisher","first-page":"204ra129","DOI":"10.1126\/scitranslmed.3006245","volume":"5","author":"K Wolk","year":"2013","unstructured":"Wolk K, Witte K, Witte E, Raftery M, Kokolakis G, Philipp S, et al. IL-29 is produced by TH17 cells and mediates the cutaneous antiviral competence in psoriasis. Sci Transl Med. 2013;5(204):204ra129.","journal-title":"Sci Transl Med"},{"issue":"6870","key":"2509_CR18","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/415389a","volume":"415","author":"M Zasloff","year":"2002","unstructured":"Zasloff M. Antimicrobial peptides of multicellular organisms. Nature. 2002;415(6870):389\u201395. https:\/\/doi.org\/10.1038\/415389a.","journal-title":"Nature."},{"issue":"3","key":"2509_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/rr25","volume":"1","author":"R Bals","year":"2000","unstructured":"Bals R. Epithelial antimicrobial peptides in host defense against infection. Respir Res. 2000;1(3):1\u201310.","journal-title":"Respir Res"},{"issue":"1","key":"2509_CR20","doi-asserted-by":"publisher","first-page":"50","DOI":"10.4103\/2277-9175.114192","volume":"2","author":"P Mendez-Samperio","year":"2013","unstructured":"Mendez-Samperio P. Recent advances in the field of antimicrobial peptides in inflammatory diseases. Adv Biomed Res. 2013;2(1):50. https:\/\/doi.org\/10.4103\/2277-9175.114192.","journal-title":"Adv Biomed Res"},{"issue":"3","key":"2509_CR21","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1128\/AAC.01650-12","volume":"57","author":"J Noore","year":"2013","unstructured":"Noore J, Noore A, Li B. Cationic antimicrobial peptide LL-37 is effective against both extra- and intracellular Staphylococcus aureus. Antimicrob Agents Chemother. 2013;57(3):1283\u201390. https:\/\/doi.org\/10.1128\/AAC.01650-12.","journal-title":"Antimicrob Agents Chemother"},{"issue":"15","key":"2509_CR22","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1056\/NEJMoa021481","volume":"347","author":"PY Ong","year":"2002","unstructured":"Ong PY, Ohtake T, Brandt C, Strickland I, Boguniewicz M, Ganz T, Gallo RL, Leung DYM. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med. 2002;347(15):1151\u201360. https:\/\/doi.org\/10.1056\/NEJMoa021481.","journal-title":"N Engl J Med"},{"issue":"3","key":"2509_CR23","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1002\/path.1224","volume":"198","author":"F Paulsen","year":"2002","unstructured":"Paulsen F, Pufe T, Conradi L, Varoga D, Tsokos M, Papendieck J, Petersen W. Antimicrobial peptides are expressed and produced in healthy and inflamed human synovial membranes. J Pathol. 2002;198(3):369\u201377. https:\/\/doi.org\/10.1002\/path.1224.","journal-title":"J Pathol"},{"issue":"12","key":"2509_CR24","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1093\/rheumatology\/ket315","volume":"52","author":"M Carri\u00f3n","year":"2013","unstructured":"Carri\u00f3n M, Juarranz Y, Mart\u00ednez C, Gonz\u00e1lez-\u00c1lvaro I, Pablos JL, Guti\u00e9rrez-Ca\u00f1as I, Gomariz RP. IL-22\/IL-22R1 axis and S100A8\/A9 alarmins in human osteoarthritic and rheumatoid arthritis synovial fibroblasts. Rheumatology. 2013;52(12):2177\u201386. https:\/\/doi.org\/10.1093\/rheumatology\/ket315.","journal-title":"Rheumatology."},{"issue":"6","key":"2509_CR25","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.coi.2007.07.020","volume":"19","author":"E Bettelli","year":"2007","unstructured":"Bettelli E, Korn T, Kuchroo VK. Th17: the third member of the effector T cell trilogy. Curr Opin Immunol. 2007;19(6):652\u20137. https:\/\/doi.org\/10.1016\/j.coi.2007.07.020.","journal-title":"Curr Opin Immunol"},{"issue":"8","key":"2509_CR26","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/nri1153","volume":"3","author":"J-C Renauld","year":"2003","unstructured":"Renauld J-C. Class II cytokine receptors and their ligands: key antiviral and inflammatory modulators. Nat Rev Immunol. 2003;3(8):667\u201376. https:\/\/doi.org\/10.1038\/nri1153.","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"2509_CR27","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.jaad.2016.01.013","volume":"74","author":"KA Papp","year":"2016","unstructured":"Papp KA, Krueger JG, Feldman SR, Langley RG, Thaci D, Torii H, Tyring S, Wolk R, Gardner A, Mebus C, Tan H, Luo Y, Gupta P, Mallbris L, Tatulych S. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study. J Am Acad Dermatol. 2016;74(5):841\u201350. https:\/\/doi.org\/10.1016\/j.jaad.2016.01.013.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"2509_CR28","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1111\/bjd.14018","volume":"173","author":"KA Papp","year":"2015","unstructured":"Papp KA, Menter MA, Abe M, Elewski B, Feldman SR, Gottlieb AB, Langley R, Luger T, Thaci D, Buonanno M, Gupta P, Proulx J, Lan S, Wolk R, the OPT Pivotal 1 and OPT Pivotal 2 investigators. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials. Br J Dermatol. 2015;173(4):949\u201361. https:\/\/doi.org\/10.1111\/bjd.14018.","journal-title":"Br J Dermatol"},{"key":"2509_CR29","doi-asserted-by":"publisher","unstructured":"\u00c1lvaro-Gracia JM, Garc\u00eda-Llorente JF, Valderrama M, Gomez S, Montoro M. Update on the safety profile of tofacitinib in rheumatoid arthritis from clinical trials to real-world studies: a narrative review. Rheumatol Ther. 2021;8(1):17\u201340. https:\/\/doi.org\/10.1007\/s40744-020-00258-9.","DOI":"10.1007\/s40744-020-00258-9"},{"key":"2509_CR30","doi-asserted-by":"publisher","unstructured":"Heinrich PC, Behrmann I, M\u00dcLler-Newen G, Schaper F, Graeve L. Interleukin-6-type cytokine signalling through the gp130\/Jak\/STAT pathway. Biochem J 1998;334(2):297\u2013314, doi: https:\/\/doi.org\/10.1042\/bj3340297.","DOI":"10.1042\/bj3340297"},{"issue":"28","key":"2509_CR31","doi-asserted-by":"publisher","first-page":"20059","DOI":"10.1074\/jbc.R700016200","volume":"282","author":"C Schindler","year":"2007","unstructured":"Schindler C, Levy DE, Decker T. JAK-STAT signaling: from interferons to cytokines. J Biol Chem. 2007;282(28):20059\u201363. https:\/\/doi.org\/10.1074\/jbc.R700016200.","journal-title":"J Biol Chem"},{"issue":"7357","key":"2509_CR32","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/nature10228","volume":"475","author":"E Esplugues","year":"2011","unstructured":"Esplugues E, Huber S, Gagliani N, Hauser AE, Town T, Wan YY, O\u2019Connor W, Rongvaux A, van Rooijen N, Haberman AM, Iwakura Y, Kuchroo VK, Kolls JK, Bluestone JA, Herold KC, Flavell RA. Control of TH17 cells occurs in the small intestine. Nature. 2011;475(7357):514\u20138. https:\/\/doi.org\/10.1038\/nature10228.","journal-title":"Nature."},{"issue":"7","key":"2509_CR33","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1084\/jem.20082584","volume":"206","author":"Y Yang","year":"2009","unstructured":"Yang Y, Weiner J, Liu Y, Smith AJ, Huss DJ, Winger R, Peng H, Cravens PD, Racke MK, Lovett-Racke AE. T-bet is essential for encephalitogenicity of both Th1 and Th17 cells. J Exp Med. 2009;206(7):1549\u201364. https:\/\/doi.org\/10.1084\/jem.20082584.","journal-title":"J Exp Med"},{"issue":"10","key":"2509_CR34","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/ni.2416","volume":"13","author":"Y Lee","year":"2012","unstructured":"Lee Y, Awasthi A, Yosef N, Quintana FJ, Xiao S, Peters A, Wu C, Kleinewietfeld M, Kunder S, Hafler DA, Sobel RA, Regev A, Kuchroo VK. Induction and molecular signature of pathogenic TH17 cells. Nat Immunol. 2012;13(10):991\u20139. https:\/\/doi.org\/10.1038\/ni.2416.","journal-title":"Nat Immunol"},{"issue":"6","key":"2509_CR35","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.coi.2011.08.007","volume":"23","author":"A Peters","year":"2011","unstructured":"Peters A, Lee Y, Kuchroo VK. The many faces of Th17 cells. Curr Opin Immunol. 2011;23(6):702\u20136. https:\/\/doi.org\/10.1016\/j.coi.2011.08.007.","journal-title":"Curr Opin Immunol"},{"issue":"12","key":"2509_CR36","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1111\/all.13972","volume":"74","author":"HC Hawerkamp","year":"2019","unstructured":"Hawerkamp HC, Kislat A, Gerber PA, Pollet M, Rolfes KM, Soshilov AA, Denison MS, Momin AA, Arold ST, Datsi A, Braun SA, Ol\u00e1h P, Lacouture ME, Krutmann J, Haarmann-Stemmann T, Homey B, Meller S. Vemurafenib acts as an aryl hydrocarbon receptor antagonist: implications for inflammatory cutaneous adverse events. Allergy. 2019;74(12):2437\u201348. https:\/\/doi.org\/10.1111\/all.13972.","journal-title":"Allergy."},{"issue":"5","key":"2509_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/ar4067","volume":"14","author":"F Wang","year":"2012","unstructured":"Wang F, Xu L, Feng X, Guo D, Tan W, Zhang M. Interleukin-29 modulates proinflammatory cytokine production in synovial inflammation of rheumatoid arthritis. Arthritis Res Ther. 2012;14(5):1\u201310.","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"2509_CR38","doi-asserted-by":"publisher","first-page":"R170-R","DOI":"10.1186\/ar4357","volume":"15","author":"L Xu","year":"2013","unstructured":"Xu L, Feng X, Tan W, Gu W, Guo D, Zhang M, et al. IL-29 enhances Toll-like receptor-mediated IL-6 and IL-8 production by the synovial fibroblasts from rheumatoid arthritis patients. Arthritis Res Ther. 2013;15(5):R170-R.","journal-title":"Arthritis Res Ther"},{"key":"2509_CR39","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.critrevonc.2016.08.002","volume":"106","author":"NE Kelm","year":"2016","unstructured":"Kelm NE, Zhu Z, Ding VA, Xiao H, Wakefield MR, Bai Q, Fang Y. The role of IL-29 in immunity and cancer. Crit Rev Oncol Hematol. 2016;106:91\u20138. https:\/\/doi.org\/10.1016\/j.critrevonc.2016.08.002.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"2509_CR40","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1002\/art.39818","volume":"69","author":"Y Furumoto","year":"2017","unstructured":"Furumoto Y, Smith CK, Blanco L, Zhao W, Brooks SR, Thacker SG, et al. Tofacitinib ameliorates murine lupus and its associated vascular dysfunction. Arthritis Rheumatol (Hoboken). 2017;69(1):148\u201360.","journal-title":"Arthritis Rheumatol (Hoboken)"},{"issue":"1","key":"2509_CR41","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1159\/000430330","volume":"37","author":"D Xu","year":"2015","unstructured":"Xu D, Yan S, Wang H, Gu B, Sun K, Yang X, Sun B, Wang X. IL-29 enhances LPS\/TLR4-mediated inflammation in rheumatoid arthritis. Cell Physiol Biochem. 2015;37(1):27\u201334. https:\/\/doi.org\/10.1159\/000430330.","journal-title":"Cell Physiol Biochem"},{"issue":"5","key":"2509_CR42","doi-asserted-by":"publisher","first-page":"R170","DOI":"10.1186\/ar4357","volume":"15","author":"L Xu","year":"2013","unstructured":"Xu L, Feng X, Tan W, Gu W, Guo D, Zhang M, Wang F. IL-29 enhances Toll-like receptor-mediated IL-6 and IL-8 production by the synovial fibroblasts from rheumatoid arthritis patients. Arthritis Res Ther. 2013;15(5):R170. https:\/\/doi.org\/10.1186\/ar4357.","journal-title":"Arthritis Res Ther."},{"issue":"8","key":"2509_CR43","doi-asserted-by":"publisher","first-page":"772","DOI":"10.2340\/00015555-2960","volume":"98","author":"A Srivastava","year":"2018","unstructured":"Srivastava A, Stahle M, Pivarcsi A, Sonkoly E. Tofacitinib represses the Janus kinase-signal transducer and activators of transcription signalling pathway in keratinocytes. Acta Derm Venereol. 2018;98(8):772\u20135. https:\/\/doi.org\/10.2340\/00015555-2960.","journal-title":"Acta Derm Venereol"},{"issue":"2","key":"2509_CR44","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.bbrc.2011.12.156","volume":"418","author":"H Yoshida","year":"2012","unstructured":"Yoshida H, Kimura A, Fukaya T, Sekiya T, Morita R, Shichita T, Inoue H, Yoshimura A. Low dose CP-690,550 (tofacitinib), a pan-JAK inhibitor, accelerates the onset of experimental autoimmune encephalomyelitis by potentiating Th17 differentiation. Biochem Biophys Res Commun. 2012;418(2):234\u201340. https:\/\/doi.org\/10.1016\/j.bbrc.2011.12.156.","journal-title":"Biochem Biophys Res Commun"},{"key":"2509_CR45","first-page":"2155","volume":"4","author":"M Hak-Ling","year":"2013","unstructured":"Hak-Ling M, Katherine M-H, Susan F, Lee N, Eva N, Saifur R, et al. Attenuating Janus kinases (JAK) by tofacitinib effectively prevented psoriasis pathology in various mouse skin inflammation models. Clin Cell Immunol. 2013;4:2155\u20139899.","journal-title":"Clin Cell Immunol"},{"issue":"7","key":"2509_CR46","doi-asserted-by":"publisher","first-page":"4234","DOI":"10.4049\/jimmunol.1003668","volume":"186","author":"K Ghoreschi","year":"2011","unstructured":"Ghoreschi K, Jesson MI, Li X, Lee JL, Ghosh S, Alsup JW, Warner JD, Tanaka M, Steward-Tharp SM, Gadina M, Thomas CJ, Minnerly JC, Storer CE, LaBranche TP, Radi ZA, Dowty ME, Head RD, Meyer DM, Kishore N, O\u2019Shea JJ. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol. 2011;186(7):4234\u201343. https:\/\/doi.org\/10.4049\/jimmunol.1003668.","journal-title":"J Immunol"},{"key":"2509_CR47","doi-asserted-by":"publisher","unstructured":"Cerboni S, Gehrmann U, Preite S, Mitra S. Cytokine-regulated Th17 plasticity in human health and diseases. Immunology. 2020; https:\/\/doi.org\/10.1111\/imm.13280.","DOI":"10.1111\/imm.13280"},{"issue":"6","key":"2509_CR48","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1002\/art.34329","volume":"64","author":"K Maeshima","year":"2011","unstructured":"Maeshima K, Yamaoka K, Kubo S, Nakano K, Iwata S, Saito K, Ohishi M, Miyahara H, Tanaka S, Ishii K, Yoshimatsu H, Tanaka Y. The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-\u03b3 and interleukin-17 production by human CD4+ T cells. Arthritis Rheumatism. 2011;64(6):1790\u20138. https:\/\/doi.org\/10.1002\/art.34329.","journal-title":"Arthritis Rheumatism"},{"issue":"6","key":"2509_CR49","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1002\/eji.201646837","volume":"47","author":"D Cibri\u00e1n","year":"2017","unstructured":"Cibri\u00e1n D, S\u00e1nchez-Madrid F. CD69: from activation marker to metabolic gatekeeper. Eur J Immunol. 2017;47(6):946\u201353. https:\/\/doi.org\/10.1002\/eji.201646837.","journal-title":"Eur J Immunol"},{"key":"2509_CR50","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jaut.2014.05.007","volume":"55","author":"JR Cort\u00e9s","year":"2014","unstructured":"Cort\u00e9s JR, S\u00e1nchez-D\u00edaz R, Bovolenta ER, Barreiro O, Lasarte S, Matesanz-Mar\u00edn A, Toribio ML, S\u00e1nchez-Madrid F, Mart\u00edn P. Maintenance of immune tolerance by Foxp3+ regulatory T cells requires CD69 expression. J Autoimmun. 2014;55:51\u201362. https:\/\/doi.org\/10.1016\/j.jaut.2014.05.007.","journal-title":"J Autoimmun"},{"issue":"20","key":"2509_CR51","doi-asserted-by":"publisher","first-page":"4877","DOI":"10.1128\/MCB.00456-10","volume":"30","author":"P Mart\u00edn","year":"2010","unstructured":"Mart\u00edn P, G\u00f3mez M, Lamana A, Cruz-Adalia A, Ram\u00edrez-Huesca M, Ursa M\u00c1, et al. CD69 association with Jak3\/Stat5 proteins regulates Th17 cell differentiation. Mol Cell Biol. 2010;30(20):4877\u201389. https:\/\/doi.org\/10.1128\/MCB.00456-10.","journal-title":"Mol Cell Biol"},{"key":"2509_CR52","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/82_2010_31","volume":"342","author":"A Weinberg","year":"2010","unstructured":"Weinberg A, Levin MJ. VZV T cell-mediated immunity. Curr Top Microbiol Immunol. 2010;342:341\u201357. https:\/\/doi.org\/10.1007\/82_2010_31.","journal-title":"Curr Top Microbiol Immunol"},{"key":"2509_CR53","doi-asserted-by":"publisher","unstructured":"Sen N, Sung P, Panda A, Arvin AM. Distinctive roles for type I and type II interferons and interferon regulatory factors in the host cell defense against varicella-zoster virus. J Virol. 2018;92(21):e01151\u201318. https:\/\/doi.org\/10.1128\/JVI.01151-18.","DOI":"10.1128\/JVI.01151-18"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-021-02509-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-021-02509-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-021-02509-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T07:04:54Z","timestamp":1621580694000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-021-02509-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,21]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2509"],"URL":"https:\/\/doi.org\/10.1186\/s13075-021-02509-8","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,21]]},"assertion":[{"value":"5 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The guidelines of the Declaration of Helsinki were deployed, and the study was authorized by the local ethics committee (No: 5775R).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"144"}}